

# A SUSTAINABLE CHOICE FOR PATIENTS AND THE PLANET

The climate impact associated with medications is becoming an increasingly important aspect to consider in the healthcare and pharmaceutical industries. The Global Initiative for Asthma (GINA) recommends considering the environmental impact of inhalers as part of deciding which inhaler to choose for patients.<sup>1</sup> Easyhaler® is a carbon neutral, multidose dry powder inhaler developed for the treatment of asthma and chronic obstructive pulmonary disease.<sup>2-4</sup>



**BUFOMIX  
EASYHALER®**  
(Budesonide/formoterol fumarate dihydrate)

**SALFLUMIX  
EASYHALER®**  
(Fluticasone propionate/salmeterol xinafoate)



## EASY TO TEACH LEARN AND USE<sup>5-9</sup>

Errors in inhaler use are common and can compromise successful therapy.<sup>5,10</sup> The majority of patients learn the **correct use of Easyhaler in less than 5 minutes.**<sup>5-8</sup>



## ACCURATE AND CONSISTENT

Generates accurate and consistent dose delivery, even with low inhalation flows.<sup>11-13</sup> Peak inspiratory flow rate of 30 L/min is sufficient for drug delivery with Easyhaler.<sup>14-15</sup>



## PREFERRED BY PATIENTS

The majority of patients are satisfied with Easyhaler following a switch from an alternative inhaler and approximately **three out of four patients prefer Easyhaler over their previous inhaler.**<sup>5,7,8,16-18</sup>




## ENVIRONMENTALLY SUSTAINABLE

A carbon neutral inhaler – **a sustainable choice for the climate.**<sup>4</sup>

SCAN THE QR CODE TO ACCESS CLINICAL INFORMATION, INSTRUCTIONS FOR USE OR TO ORDER A DEMO DEVICE.



## EASYHALER® PROVIDES ACCURATE AND CONSISTENT DOSE DELIVERY EVEN WITH LOW INHALATION FLOWS



**Easyhaler combination product provides more consistent dose delivery than Turbuhaler at three different patient inhalation flow rates ( $P<0.001$ ).<sup>11</sup>**

PIF, peak inspiratory flow

Study conducted *in vitro* comparing Buformix Easyhaler to budesonide/formoterol Turbuhaler at 160ug/4.5ug dose. 36 inhalers of each product were used comparing the effect of flow rate; six inhalers for each of the three flow rates for uniformity of delivered dose, fine particle dose, mass median aerodynamic diameter and geometric standard deviation.

### QUICK AND SIMPLE TO USE




SCAN THE QR CODE  
TO WATCH  
EASYHALER  
IN ACTION


#### 1. SHAKE



#### 2. CLICK



#### 3. INHALE



**References:** 1. The Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2023. Available at: [ginasthma.org](http://ginasthma.org). 2. Salflumix Easyhaler Product Information, August 18 2023. 3. Buformix Easyhaler Product Information, July 17 2023. 4. Carbon Neutral Product Certificate for Easyhaler product range. Available on request from Orion Pharma. 5. Tamási L, et al. *Adv Ther*. 2018;35:1140-1152. 6. Gálffy G, et al. *Pulm Ther*. 2019;5:165-177. 7. Gálffy G, et al. *Drugs in R&D*. 2013;13:215-222. 8. Syk J, et al. *Adv Ther*. 2019;36:1756-1769. 9. Hantulik P, et al. *Pneumol Alergol Pol*. 2015;83:365-377. 10. Ribó P, et al. *NPJ Prim Care Respir Med*. 2020;30:33-40. 11. Haikarainen J, et al. *Pulm Ther* 2017;3:125-38. 12. Haikarainen J, et al. *Chron Respir Dis* 2018;15:265-71. 13. Palander A, et al. *Clin Drug Invest*. 2000;20:25-33. 14. Malmberg LP, et al. *J Thorac Dis*. 2021;13:621-631. 15. Kainu A, et al. *Pulm Ther*. 2024;10:133-142. 16. Valero A, et al. *Expert Rev Respir Med*. 2019;13:133-38. 17. Alvarez-Gutiérrez FJ, et al. *Patient Prefer Adherence*. 2021;15:349-358. 18. Vinge I, et al. *Ther Adv Respir Dis*. 2021;15:1-12. 19. Ghosh S, et al. *J Aerosol Med Pulm Drug Deliv*. 2017;30:381-387. 20. Haidl P, et al. *Respir Med*. 2016;118:65-75.

PBS information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.

**Before prescribing, please review the full Product Information available via the QR codes or from**

<https://www.orionpharma.com.au/products/primary-care-products>



BUFOMIX  
PRODUCT  
INFORMATION



SALFLUMIX  
PRODUCT  
INFORMATION

EASYHALER® is a registered trademark of Orion Corporation Finland.  
Orion Pharma, Level 24, Tower 3, 300 Barangaroo Ave Sydney NSW 2000 Australia  
[www.orionpharma.com.au](http://www.orionpharma.com.au) | [contactausaustralia@orionpharma.com](mailto:contactausaustralia@orionpharma.com) For medical information or to  
report an adverse event PH: 1800 861 913 or EMAIL: [medical.ANZ@pharmalex.com](mailto:medical.ANZ@pharmalex.com)  
Date of preparation: July 2024. EH\_AU\_2024\_15

